STOCK TITAN

Clearside Biomedical Inc - CLSD STOCK NEWS

Welcome to our dedicated news page for Clearside Biomedical (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomedical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clearside Biomedical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clearside Biomedical's position in the market.

Rhea-AI Summary
Clearside Biomedical appoints seasoned biotechnology executive Anthony S. Gibney to its Board of Directors, bringing expertise in business strategy, collaborations, finance, and M&A with recent ophthalmic experience. The appointment aims to enhance Clearside's leadership in delivering therapeutics to the suprachoroidal space, particularly as the company advances towards a potential Phase 3 program for CLS-AX in wet AMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.85%
Tags
management
-
Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) executives to participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference. The event will feature President and CEO George Lasezkay and CMO Victor Chong, discussing the company's innovative therapies for eye diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.39%
Tags
conferences
-
Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) appoints Dr. Victor Chong as Chief Medical Officer, bringing extensive experience in retinal disease research and clinical development. Dr. Chong's background includes work on various retinal diseases and significant contributions to drug development, notably in wet AMD. His appointment signifies a strategic move for Clearside's suprachoroidal product development, with a focus on the upcoming ODYSSEY Phase 2b wet AMD clinical trial data analysis and Phase 3 program planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
management
Rhea-AI Summary
Clearside Biomedical, Inc. reports financial results for Q4 2023, remains on track with Phase 2b ODYSSEY Wet AMD trial, and strengthens capital position through equity offering and licensing agreement. Topline data for the ODYSSEY trial expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
-
Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) is set to report its fourth quarter and full year 2023 financial results on March 12, 2024. The company will host a webcast and conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences earnings
-
Rhea-AI Summary
Clearside Biomedical, Inc. announced a registered direct offering of 11,111,111 shares of common stock and accompanying warrants to purchase the same number of shares. The offer price for one share and accompanying warrant is $1.35, with the warrants having an exercise price of $1.62 per share. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) completes randomization in ODYSSEY Phase 2b clinical trial for CLS-AX in neovascular age-related macular degeneration (wet AMD), with topline data expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) expands its proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor through a new licensing partnership with BioCryst Pharmaceuticals. The collaboration includes $5 million upfront and the potential for additional $77.5 million in milestone payments, plus royalties. Recruitment for the CLS-AX Phase 2b ODYSSEY Wet AMD Trial is completed, with topline data expected in Q3 2024. The company's President and CEO, George Lasezkay, highlighted the strategic advancements in the internal pipeline and external collaborations, emphasizing the potential of the partnership with BioCryst to target diabetic macular edema (DME) utilizing suprachoroidal administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
-
Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) to participate in fireside chat at Stifel 2023 Healthcare Conference. CEO George Lasezkay to speak on November 15, 2023, at 8:35 a.m. ET in New York, NY. The webcast will be available on the Clearside website under the Investors section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.65%
Tags
conferences
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) presents encouraging safety and efficacy data at AAO Annual Meeting, highlighting SCS Microinjector's role in treating retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.65%
Tags
Clearside Biomedical Inc

Nasdaq:CLSD

CLSD Rankings

CLSD Stock Data

93.40M
69.25M
7.17%
21.27%
0.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Alpharetta

About CLSD

clearside biomedical, inc. is a pharmaceuticals company located in 1220 old alpharetta rd., suite 300, alpharetta, ga, united states.